Rosiglitazone for Treatment of HIV Lipodystrophy
Authors: Colleen Hadigan, Steven Grinspoon
Journal: Annals of Internal Medicine (2004)

Letters2 November 2004Rosiglitazone for Treatment of HIV LipodystrophyColleen Hadigan, MD, MPH and Steven Grinspoon, MDColleen Hadigan, MD, MPHFrom Massachusetts General Hospital, Boston, MA 02114.Search for more papers by this author and Steven Grinspoon, MDFrom Massachusetts General Hospital, Boston, MA 02114.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-141-9-200411020-00025 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We acknowledge that rosiglitazone was associated with modest but statistically significant increases in total cholesterol and LDL cholesterol levels in our study, similar to findings seen in the non-HIV diabetes literature regarding the use of this agent. It is important to recognize, however, that insulin resistance, elevated free fatty acid levels, and hypoadiponectinemia are also significant independent predictors of cardiovascular disease; all of these improved with rosiglitazone therapy in our study sample. Furthermore, evidence shows that peroxisome proliferator–activated receptor-γ (PPAR-γ) agonists increase LDL particle size and increase small high-density lipoprotein particles, thereby creating a less atherogenic lipid profile ...References1. Bavirti S, Ghanaat F, Tayek JA. Peroxisome proliferator-activated receptor-gamma agonist increases both low-density lipoprotein cholesterol particle size and small high-density lipoprotein cholesterol in patients with type 2 diabetes independent of diabetic control. Endocr Pract. 2003;9:487-93. [PMID: 14715475] CrossrefMedlineGoogle Scholar2. Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D, et al . No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet. 2004;363:429-38. [PMID: 14962523] CrossrefMedlineGoogle Scholar3. Gelato MC, Mynarcik DC, Quick JL, Steigbigel RT, Fuhrer J, Brathwaite CE, et al . Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquir Immune Defic Syndr. 2002;31:163-70. [PMID: 12394794] CrossrefMedlineGoogle Scholar4. Dube M, Zackin R, Tebas P, Roubenoff R, Mulligan K, Robbins G, et al . Prospective study of regional body composition in antiretroviral-naive subjects randomized to receive zidovudine + lamivudine or didanosine + stavudine combined with nelfinavir, efavirenz, or both: A5005s, a study of ACTG 384. Antiviral Therapy. 2002;7:L18. Google Scholar Author, Article, and Disclosure InformationAuthors: Colleen Hadigan, MD, MPH; Steven Grinspoon, MDAffiliations: From Massachusetts General Hospital, Boston, MA 02114. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoMetabolic Effects of Rosiglitazone in HIV Lipodystrophy Colleen Hadigan , Sigal Yawetz , Abraham Thomas , Fiona Havers , Paul E. Sax , and Steven Grinspoon Rosiglitazone for Treatment of HIV Lipodystrophy Nasser Mikhail Metrics 2 November 2004Volume 141, Issue 9Page: 739-740KeywordsAdipogenesisCholesterolFatsHigh density lipoproteinHyperinsulinemiaInsulin resistanceLipid profilesLipidsLipodystrophyLow density lipoprotein ePublished: 2 November 2004 Issue Published: 2 November 2004 Copyright & PermissionsCopyright © 2004 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...